Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 2, 2009, Pages 388-391

  Koh, Won Jung ^a   Kwon, O Jung ^a   Gwak, Hyesun ^b   Chung, Joo Won ^c   Cho, Sang Nae ^d   Kim, Woo Sung ^e   Shim, Tae Sun ^e  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Ewha Womans University   (South Korea)

^c Asan Medical Center   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e University of Ulsan College of Medicine   (South Korea)

Author keywords

Efficacy; MDR TB; Oxazolidinones; Tolerability; XDR TB

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CLARITHROMYCIN; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOPENIA; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PERIPHERAL NEUROPATHY; TREATMENT DURATION; TUBERCULOSIS;

ACETAMIDES; ADULT; ANTITUBERCULAR AGENTS; FEMALE; HUMANS; MALE; OXAZOLIDINONES; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 67650730258     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp171     Document Type: Article

References (20)

1. Orenstein EW, Basu S, Shah NS et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: Systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-61.
2. Kim HR, Hwang SS, Kim HJ et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007; 45: 1290-5.
3. Kwon YS, Kim YH, Suh GY et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 2008; 47: 496-502.
4. Kim DH, Kim HJ, Park SK et al. Treatment outcomes and longterm survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2008; 178: 1075-82.
5. Fortun J, Martin-Davila P, Navas E et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005; 56: 180-5.
6. von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB) - a report of ten cases. J Infect 2006; 52: 92-6.
7. Yew WW, Chau CH,Wen KH. Linezolid in the treatment of 'difficult' multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008; 12: 345-6.
8. Condos R, Hadgiangelis N, Leibert E et al. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 2008; 134: 187-92.
9. Eker B, Ortmann J, Migliori GB et al. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis 2008; 14 1700-6.
10. Park IN, Hong SB, Oh YM et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006; 58: 701-4.
11. Nam HS, Koh WJ, Kwon OJ et al. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis. Int J Antimicrob Agents 2009; 33: 92-3.
12. Boak LM, Li J, Nation RL et al. High-performance liquid chromatographic method for simple and rapid determination of linezolid in human plasma. Biomed Chromatogr 2006; 20: 782-6.
13. National Committee for Clinical Laboratory Standards. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes: Approved Standard M24-A. NCCLS, Wayne, PA, USA, 2003.
14. McWhirter JP, Pennington CR. Incidence and recognition of malnutrition in hospital. BMJ 1994; 308: 945-8.
15. Laserson KF, Thorpe LE, Leimane V et al. Speaking the same language: Treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640-5.
16. Bressler AM, Zimmer SM, Gilmore JL et al. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004; 4: 528-31.
17. Stalker DJ, Jungbluth GL, Hopkins NK et al. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 2003; 51: 1239-46.
18. Honeybourne D, Tobin C, Jevons G et al. Intrapulmonary penetration of linezolid. J Antimicrob Chemother 2003; 51: 1431-4.
19. De Vriese AS, Coster RV, Smet J et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 2006; 42: 1111-7.
20. McKee EE, Ferguson M, Bentley AT et al. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother 2006; 50: 2042-9.